- About us
- Clinical trials
- News & Publications
The design of SOT101 (formerly SO-C101) enables its fusion to monoclonal antibodies, allowing it to precisely target tumor antigens, tumor stroma or T cells. As a result, SOTIO is developing SOT201 (formerly SO-C108), an immunocytokine fusing a proprietary IL-15 superagonist to an anti-PD-1 antibody in order to directly target T cells. This fusion allows for spatial colocalization of an IL-15 superagonist with an anti-PD-1 checkpoint inhibitor, to best enhance their synergistic modes of action and potentially improve outcomes. SOT201 is one of the first IL-15/PD-1 targeting immunocytokines.
Preclinical data indicates SOT201 (SO-C108) administration has a different mode of action and addresses other indications in addition to the administration of SOT101 (SO-C101) and an anti-PD-1 antibody in combination.